NSAIDs have long been the cornerstone of pharmaceutical pain relief for dogs with OA. But with the arrival of an OA monoclonal antibody therapy, is it time to rethink our approach? In this episode of Clinician’s Brief Partner Podcast, Dr. Beth invites renowned orthopedic expert Dr. John Innes to discuss how he approaches OA management, drawing from >4 years of experience with bedinvetmab in the United Kingdom. They also dive into a head-to-head study comparing bedinvetmab with an NSAID and explore what the findings mean for today’s treatment strategies. 

Sponsored by Zoetis

Contact us:

• Podcast@instinct.vet

Where to find us:

• Cliniciansbrief.com/podcasts
• Facebook.com/clinciansbrief
• Twitter: @cliniciansbrief
• Instagram: @clinicians.brief

The Team:

• Beth Molleson, DVM - Host
• Sarah Pate - Producer & Project Manager, Brief Studio
• Taylor Argo - Podcast Production & Sound Editing

LIBRELA IMPORTANT SAFETY INFORMATION: For use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid selfinjection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Librela should not be used in breeding, pregnant or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to bedinvetmab. The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis. See full Prescribing Information at LibrelaPI.com